March wasn't kind to many of biotech's hottest names. From Geron (NASDAQ:GERN) to Exelixis (NASDAQ:EXEL), many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while investors can be excused for taking profits, were some of March's biggest losers victims of unfortunate timing or real reasons for concern?

Geron suffered perhaps the worst loss of the month by plunging more than 50% after the FDA placed a clinical hold on the company's developmental drug Imetelstat, but it was hardly the only up-and-coming biotech to endure a big fall. Do March's biggest losses signal a great buying opportunity for savvy investors, however? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through three of the past month's biggest losers -- and whether or not they can bounce back for your portfolio's gain.

The 1 under-the-radar growth opportunity you won't want to miss!
Smart biotech investors understand a simple truth about the market: Opportunities to get wealthy from a single investment don't come around often, but they do exist. Our chief technology officer believes he's found one. In the Motley Fool's latest free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Exelixis and Johnson & Johnson. The Motley Fool owns shares of Exelixis and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers